Top Biotech Companies in Vancouver (41)
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give...
Jazz Pharmaceuticals, Inc's Top Stability & Growth Strengths
Strong Market Position & Advantage: Jazz is described as a clear leader in rare sleep disorders through its oxybate franchise (Xywav/Xyrem and authorized generics royalties) and in cannabinoid-based epilepsy with Epidiolex surpassing $1B in 2025. Xywav’s idiopathic hypersomnia approval with orphan exclusivity and category-leading revenue reinforce defensibility.
Strong Revenue Growth: Record 2025 revenue around $4.27 billion and a record Q4, with 2026 guidance still pointing up, indicate sustained top-line momentum. Company communications highlight a multi-year streak of annual growth continuing into 2026.
Diversified Revenue Streams: A balanced base with rare sleep revenues above $2B, Epidiolex above $1B, and roughly $1.13B in oncology plus new contributions from Modeyso and royalties shows multiple revenue pillars. Pipeline drivers like zanidatamab and Zepzelca label expansion add additional avenues.
STEMCELL Technologies is a Canadian biotechnology company that helps power leading-edge life science research around the world. Driven by our love of science and passion for quality, we are Scientists Helping Scientists—standing by our customers to provide the outstanding products, technical support, and training they need to advance their research. Scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular...
Acuitas is the premier LNP (lipid nanoparticle) technology provider, enabling our partners to advance new therapeutics to address unmet clinical needs. We have developed a broad IP portfolio focussed on the use of LNP technology for nucleic acid therapeutics. This portfolio primarily encompasses novel compositions of matter but also includes novel uses of nucleic acids therapeutics. Our mission is · To...
Dexcom Corporation is a pioneer and global leader in continuous glucose monitoring (CGM). Dexcom began as a small company with a big dream: To forever change how diabetes is managed. To unlock information and insights that drive better health outcomes. Here we are 25 years later, having pioneered an industry. And we're just getting started. We are broadening our...
Dexcom's Top Stability & Growth Strengths
Strong Market Position & Advantage: Dexcom is repeatedly portrayed as a co-leader globally and the U.S. leader in CGM, supported by deep integrations with automated insulin delivery systems and a durable duopoly structure. This positioning reflects sustained adoption of its G7 platform and scale advantages.
Strong Revenue Growth: Recent results and guidance indicate consistent double-digit year-over-year growth with expanding margins. Management communications highlight ongoing momentum into 2026 supported by continued platform rollouts.
Market Expansion: The launch of an over-the-counter sensor and extended-wear G7 broaden addressable users beyond intensive insulin therapy. International uptake and clinical data in non‑insulin type 2 populations further extend the growth runway.
Gandeeva Therapeutics is a precision biotechnology company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline...
Microbiome Insights, Inc. is a leading global provider of end-to-end services for microbiome DNA sequencing, including state-of-the-art bioinformatic analysis. The company's customized suite of services enables researchers and clinicians to easily and effectively include microbiome analysis in studies across a range of human, animal, agricultural, and environmental applications. The multidisciplinary team of researchers and knowledge leaders at the company's helm...
Avivo, a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. This innovative platform enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s platform will enable healthcare providers...
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to...
Amgen's Top Stability & Growth Strengths
Strong Revenue Growth: 2025 results show total revenues up 10% to $36.8 billion and guidance for 2026 at $37.0–$38.4 billion signals continued top‑line expansion.
Diversified Revenue Streams: Company updates indicate a broad base with roughly 40 marketed products and 14 blockbusters in 2024, and in 2025 eighteen products reached record sales with notable growth from Repatha, TEZSPIRE, EVENITY, BLINCYTO, and rare‑disease brands.
Strong Market Position & Advantage: Evidence suggests Amgen is widely regarded as a leader among large‑cap biotechs with significant scale and an expanded rare‑disease footprint following the Horizon acquisition.
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life.
SaNOtize has developed and patented (issued) a Nitric Oxide Releasing Solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Target indications include treatment for strep throat, athlete's foot, infected wounds, diabetic foot ulcers, sinusitis, cold and flu and others. With antibiotic resistance increasing in the world, SaNOtize's platform technology can help fight resistance and bring a...
Vesalius Cardiovascular is a Canadian medical device company founded in 2016 in Vancouver, Canada. The company specializes in designing and developing biomedical devices for the treatment of cardiovascular disease, specifically mitral valve regurgitation (MR). We are preclinical. Our devices will be introduced percutaneously (transfemoral/transseptal) to the heart, eliminating the need for open heart surgery and the related risks. The procedure...
Notch is an early-stage biotech company, working to maximize the benefit of cell therapies through a proprietary T cell-production platform which combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch’s iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design...
Bold Therapeutics is the world leader in the development of novel metallotherapeutics. Bold Therapeutics' lead program, BOLD-100, has demonstrated positive safety and efficacy in Phase 2 clinical trials in colorectal, biliary tract and gastric cancers, with presentations at ASCO 2024 and ASCO GI 2024. Bold Therapeutics expects to initiate pivotal Phase 3 trials in the near future.
Biological Software is one or more synthetic molecules that execute complex functions, specified from a program, in a biological system. We are creating tools to develop increasingly powerful biological software for the rational design of novel, broadly accessible medicines and biotechnologies previously out of reach. Our antedisciplinary team of scientists, machine learning researchers, engineers and entrepreneurs is growing. If you are excited...
Variational AI has developed Enki, the biopharma industry's first commercially-available foundation model for small molecules. Enki is based on a novel generative AI framework invented by Variational AI that has delivered novel and selective leads to multiple biopharma partners and customers.
Mobcoder is a global technology company specializing in AI development and innovative solutions. Since 2014, we've launched over 300 apps, empowering businesses across various industries and locations.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.
Xylem |ˈzīləm| 1) The tissue in plants that brings water upward from the roots; 2) a leading global water technology company. Xylem, a leading global water technology company dedicated to solving the world’s most challenging water issues, is the leading global provider of efficient, innovative and sustainable water technologies improving the way water is used, managed, conserved and re-used. Our international team is...
Cytel enables decision-makers in the life sciences to unlock the full potential of their products. From navigating uncertainty to proving value, Cytel’s 30 years of global expertise in consulting, data-driven analytics, and industry-leading software helps biotech and pharmaceutical companies transform intelligence into confident decisions. We have an uncompromising commitment to scientific rigor and high standards of operational excellence, which are...
Cytel's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Private-equity ownership by Astorg and Nordic Capital is positioned as support to accelerate Cytel’s next phase of growth and innovation, signaling access to growth-oriented capital and sponsorship.
Product Line Growth: East Horizon launched as a cloud-based evolution of Cytel’s trial-design software and has continued adding modules through 2025, indicating ongoing investment and expansion of the software offering.
Market Expansion: Multiple acquisitions in 2022–2023 (e.g., Stève Consultants and co.faktor) and an increase in offices from 2021 to 2023 indicate broader geographic coverage and capability expansion, particularly across Europe.
Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. We leverage our world-class delivery systems and related technologies to bring new medicines to patients who need them. We do this by selectively collaborating with leading pharma and biotech...
































